- Country: Belgium
- Summary: Framework Agreement for the Supply of Doxorubicin Liposomal
- BET Ref No: 82000817
- Deadline: 24 May 2023
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: EUR 396866.58
- Notice Type: Tender
- Document Ref. No.: 239366-2023
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- zie II.2.4
Doc Title: Antibiotics and chemotherapeutics for dermatological use
Contract Type: Supplies - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINFramework Agreement for the Supply of Doxorubicin Liposomal - Belgium Tender
The ONZE-LIEVE-VROUWZIEKENHUIS V.Z.W. (WITH CAMPUSES IN AALST, ASSE AND NINOVE), a Government sector organization in Belgium, has announced a new tender for Framework Agreement for the Supply of Doxorubicin Liposomal. This tender is published on BelgiumTenders under BET Ref No: 82000817 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-05-24.
The estimated tender value is EUR 396866.58, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
